141 results on '"Desrayaud, Sandrine"'
Search Results
2. Developing Low Molecular Weight PET and SPECT Imaging Agents.
3. Improving In Vitro-In VivoExtrapolation (IVIVE) of Clearance Using Rat Liver Microsomes for Highly Plasma Protein Bound Molecules
4. Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors
5. 4. How solubility influences bioavailability
6. Modulation of Oral Bioavailability and Metabolism for Closely Related Cyclic Hexapeptides
7. Improving In Vitro–In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound Molecules
8. Micropreparative isolation and NMR structure elucidation of metabolites of the drug candidate 1-isopropyl-4-(4-isopropylphenyl)-6-(prop-2-yn-1-yloxy) quinazolin-2(1H)-one from rat bile and urine
9. A practical approach to the optimization of positron emission tomography imaging agents for the central nervous system
10. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: Identification, SAR and pharmacological characterization
11. Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945
12. Predicting In Vivo Compound Brain Penetration Using Multi-task Graph Neural Networks
13. Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor
14. Brain Penetration of SDZ PSC 833 in Rats : A Comparison with Cyclosporin A
15. Siponimod Demonstrates Pro-remyelination Effects in the Mouse Cuprizone-Intoxication Model (2503)
16. MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates
17. Front Cover: Developing Low Molecular Weight PET and SPECT Imaging Agents (ChemMedChem 15/2024).
18. Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice
19. The positive allosteric modulator GS39783 enhances GABAB receptor-mediated inhibition of cyclic AMP formation in rat striatum in vivo
20. Brain Penetration of SDZ PSC 833 in Rats
21. Additional file 1:Â Figure S1-S14. of Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945
22. Design of A Metabolically Stable Tritium-Tracer of the PI3Kδ-Inhibitor CDZ173 (Leniolisib) as a Tool to Study Liver Metabolites
23. Utility of food pellets containing 1-aminobenzotriazole for longer term in vivo inhibition of cytochrome P450 in mice
24. Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors
25. Modulation of Oral Bioavailability and Metabolism for Closely Related Cyclic Hexapeptides
26. Cover Picture: Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist (ChemMedChem 3/2017)
27. Utility of food pellets containing 1-aminobenzotriazole for longer term in vivo inhibition of cytochrome P450 in mice.
28. Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: Structure based design and in vivo reduction of amyloid β-peptides
29. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2
30. Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist
31. Back Cover: Design and Development of a Cyclic Decapeptide Scaffold with Suitable Properties for Bioavailability and Oral Exposure (ChemMedChem 10/2016)
32. Design and Development of a Cyclic Decapeptide Scaffold with Suitable Properties for Bioavailability and Oral Exposure
33. Pharmacokinetic Studies around the Mono‐ and Difunctionalization of a Bioavailable Cyclic Decapeptide Scaffold
34. Discovery of 1H-pyrrolo[2,3-c]pyridine-7-carboxamides as novel, allosteric mGluR5 antagonists
35. 6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists
36. MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod)
37. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors
38. Hyperdopaminergia and altered locomotor activity in GABA-B1-deficient mice
39. Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist.
40. Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application
41. Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity
42. Macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors with activity in vivo
43. Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides
44. Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile
45. ChemInform Abstract: Piperidyl Amides as Novel, Potent and Orally Active mGlu5 Receptor Antagonists with Anxiolytic‐Like Activity.
46. The positive allosteric modulator GS39783 enhances GABABreceptor-mediated inhibition of cyclic AMP formation in rat striatumin vivo
47. The priorities/needs of the pharmaceutical industry in drug delivery to the brain
48. 6-[2-(Adamantylidene)-hydroxybenzoxazole]-O-sulfamate, a steroid sulfatase inhibitor for the treatment of androgen- and estrogen-dependent diseases
49. GABAB Receptor Antagonist-Mediated Antidepressant-Like Behavior Is Serotonin-Dependent
50. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.